ANTI-NEPRILYSIN MARKET ANALYSIS
Global Anti-Neprilysin Market : Key Developments
In December 2020, The U.S. Food and Drug Administration, the central drug regulatory authority in the U.S., announced that an expanded indication was warranted for sacubitril/valsartan that allow it as a treatment for certain patients with HF with preserved ejection fraction
In March 2021, Stragen Pharma SA, a Switzerland-based biopharmaceutical company, started enrollment of healthy volunteers in a phase II trial of STR-324 for postoperative pain. STR-324 is an anti-nephrilysin investigational new drug (IND) candidate. .
On January 18, 2023, Cipla Inc., a India-based biopharmaceutical and medical company, announced the launch of Cippoint, a point-of-care testing device. The device offers a wide range of testing parameters including cardiac markers, diabetes, infectious diseases, fertility, thyroid function, inflammation, metabolic markers, and coagulation markers. The device had been approved in August 2020, by the European In-Vitro Diagnostic Device (IVD) Directive, thus ensuring reliable testing solutions. The IVD sets out the essential safety, health, design, and manufacturing requirements that in vitro diagnostic medical devices and their accessories must meet. This ensures universally high safety standards, providing public confidence in the system. It enables the products to be used in any European Union country.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 
